SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Securities Exchange Act of 1934 (Amendment No. )
NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS
December 5, 2024
3:00 p.m. Pacific Time
Chief Executive Officer and Acting Chairman of the Board
Redwood City, California
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| | | | | 17 | | | |
| | | | | 19 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 37 | | | |
| | | | | 37 | | | |
| | | | | 37 | | |
to be held December 5, 2024
ELECTION OF DIRECTORS
Name
|
| |
Age
|
| |
Position
|
| |
Date Appointed
|
|
Nevan Charles Elam | | | 57 | | | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | |
January 31, 2013
|
|
Gil Labrucherie | | | 53 | | | Director | | |
November 20, 2019
|
|
Nerissa Kreher, M.D. | | | 52 | | | Director | | |
March 2, 2021
|
|
Philippe Fauchet | | | 66 | | | Director | | |
September 10, 2020
|
|
Wladimir Hogenhuis, M.D. | | | 60 | | | Director | | |
March 2, 2021
|
|
Young-Jin Kim | | | 67 | | | Director | | |
February 10, 2019
|
|
|
Total Number of Directors
|
| |
6
|
| |||
| | | |
Male
|
| |
Female
|
|
| Part I: Gender Identity | | | | | | | |
|
Directors
|
| |
5
|
| |
1
|
|
| Part II: Demographic Background | | | | | | | |
|
White
|
| |
3
|
| |
1
|
|
|
African American or Black
|
| |
1
|
| |
—
|
|
|
Asian
|
| |
1
|
| |
—
|
|
|
Did Not Disclose Demographic Background
|
| |
—
|
| |
—
|
|
|
Directors who are Military Veterans
|
| |
1
|
| |
—
|
|
| | |
Committee Appointments
|
| |||||||||||||||
Director Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Governance |
| |||||||||
Committee Members as of June 30, 2024: | | | | | | | | | | | | | | | | | | | |
Gil Labrucherie(1)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Nerissa Kreher(2)
|
| | | | | | | | |
|
X
|
| | | |
|
X
|
| |
Philippe Fauchet(3)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Wladimir Hogenhuis(4)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Young-Jin Kim(5)
|
| | | | | | | | | | | | | | | | | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Option
Awards ($)(6) |
| |
Total ($)
|
| |||||||||
Gil Labrucherie
|
| | | | 69,000(1) | | | | | | 24,444(7) | | | | | | 93,444 | | |
Nerissa Kreher
|
| | | | 62,000(2) | | | | | | 24,444(7) | | | | | | 86,444 | | |
Philippe Fauchet
|
| | | | 66,000(3) | | | | | | 24,444(7) | | | | | | 90,444 | | |
Wladimir Hogenhuis
|
| | | | 69,000(4) | | | | | | 24,444(7) | | | | | | 93,444 | | |
Young-Jin Kim
|
| | | | 45,000(5) | | | | | | —(8) | | | | | | 45,000 | | |
| | |
Shares Underlying
Options Outstanding |
| |||||||||
| | |
Vested
|
| |
Unvested
|
| ||||||
Gil Labrucherie
|
| | | | 70,499 | | | | | | 52,501 | | |
Nerissa Kreher
|
| | | | 67,499 | | | | | | 52,501 | | |
Philippe Fauchet
|
| | | | 67,499 | | | | | | 52,501 | | |
Wladimir Hogenhuis
|
| | | | 67,499 | | | | | | 52,501 | | |
Young-Jin Kim
|
| | | | 26,666 | | | | | | 13,334 | | |
Name of Beneficial Owner
|
| |
Position with Company
|
| |
Beneficial
Ownership |
| |
Percent
of Class |
| ||||||
Stockholders in excess of 5% | | | | | | | | | | | | | | | | |
Entities associated with Federated Hermes, Inc.
|
| |
Stockholder
|
| | | | 11,279,327(1) | | | | | | 18.97% | | |
Handok, Inc.
|
| |
Stockholder
|
| | | | 7,192,617(2) | | | | | | 12.86% | | |
Nantahala Capital Management LLC
|
| |
Stockholder
|
| | | | 5,875,463(3) | | | | | | 9.99% | | |
Vivo Opportunity Fund Holdings, L.P.
|
| |
Stockholder
|
| | | | 2,797,704(4) | | | | | | 5.00% | | |
Directors and Executive Officers: | | | | | | | | | | | | | | | | |
Nevan Charles Elam
|
| |
Chief Executive Officer,
Acting Chair of the Board of Directors |
| | | | 2,248,094(5) | | | | | | 3.86% | | |
Gil Labrucherie
|
| |
Director
|
| | | | 141,571(6) | | | | | | * | | |
Nerissa Kreher
|
| |
Director
|
| | | | 84,999(7) | | | | | | * | | |
Philippe Fauchet
|
| |
Director
|
| | | | 84,999(8) | | | | | | * | | |
Wladimir Hogenhuis
|
| |
Director
|
| | | | 126,766(9) | | | | | | * | | |
Young-Jin Kim
|
| |
Director
|
| | | | 7,341,400(10) | | | | | | 13.12% | | |
Brian Roberts
|
| |
Chief Medical Officer
|
| | | | 642,755(11) | | | | | | 1.14% | | |
Daron Evans
|
| |
Chief Financial Officer
|
| | | | 203,351(12) | | | | | | * | | |
Directors and executive officers as a group (8 people)
|
| | | | | | | 10,873,935(13) | | | | | | 18.39% | | |
| | |
Plan
Termination Date |
| |
Shares to be Issued Upon
Exercise of Outstanding Options: |
| |
Securities
Available For Future Issuance |
| ||||||||||||
| | |
Number of
Shares |
| |
Weighted Average
Exercise Price |
| |||||||||||||||
Equity compensation plans approved by security holders:
|
| | | | | | | | | | | | | | | | | | | | | |
2015 Non-Qualified Stock Option Plan
|
| |
February 23, 2020
|
| | | | 17 | | | | | $ | 19.86 | | | | | | — | | |
2016 Non-Qualified Stock Option Plan
|
| |
October 31, 2021
|
| | | | 123 | | | | | | 16.93 | | | | | | — | | |
2021 Equity Incentive Plan
|
| |
March 31, 2031
|
| | | | 10,276 | | | | | | 3.51 | | | | | | 342 | | |
2022 Employee Stock Purchase Plan
|
| |
Indefinite
|
| | | | — | | | | | | — | | | | | | 500 | | |
Equity compensation plans not approved by security holders:
|
| | | | | | | | | | | | | | | | | | | | | |
2019 Non-Qualified Stock Option Plan
|
| |
July 31, 2029
|
| | | | 200 | | | | | | 14.50 | | | | | | — | | |
Inducement Stock Option
|
| |
January 23, 2029
|
| | | | 275 | | | | | | 1.02 | | | | | | — | | |
Total
|
| | | | | | | 10,891 | | | | | | 3.82 | | | | | | 842 | | |
ACCOUNTANT PROPOSAL
| | |
2024
|
| |
2023
|
| ||||||||||||||||||
| | |
Amount
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| ||||||||||||
Audit fees(1)
|
| | | $ | 516,000 | | | | | | 95% | | | | | $ | 190,00 | | | | | | 84% | | |
Tax fees
|
| | | | 29,250 | | | | | | 5% | | | | | | 36,550 | | | | | | 16% | | |
Total
|
| | | $ | 545,250 | | | | | | 100% | | | | | $ | 226,550 | | | | | | 100% | | |
Mr. Fauchet
Dr. Hogenhuis
SAY-ON-PAY PROPOSAL
Name
|
| |
Age
|
| |
Position
|
| |
Date Appointed
|
|
Nevan Charles Elam | | |
57
|
| | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | |
January 31, 2013
|
|
Brian Roberts | | |
50
|
| | Chief Medical Officer | | |
June 1, 2022
|
|
Daron Evans | | |
51
|
| | Chief Financial Officer | | |
January 23, 2024
|
|
Name and Position(9)
|
| |
Fiscal
Year |
| |
Salary
|
| |
Bonus
|
| |
Stock
Option Awards |
| |
All Other
Compensation |
| |
Total
|
| ||||||||||||||||||
Nevan Charles Elam
|
| | | | 2024 | | | | | $ | 550,167(1) | | | | | $ | 342,228(4) | | | | | $ | 277,032(6) | | | | | $ | 23,273(7) | | | | | $ | 1,192,700 | | |
Chief Executive Officer
|
| | | | 2023 | | | | | $ | 534,112(1) | | | | | $ | 416,068(5) | | | | | $ | —(6) | | | | | $ | 23,466(7) | | | | | $ | 973,646 | | |
Brian Roberts, M.D.
|
| | | | 2024 | | | | | $ | 471,572(2) | | | | | $ | 195,559(4) | | | | | $ | 105,924(6) | | | | | $ | 44,904(8) | | | | | $ | 817,959 | | |
Chief Medical Officer
|
| | | | 2023 | | | | | $ | 457,809(2) | | | | | $ | 237,753(5) | | | | | $ | —(6) | | | | | $ | 43,296(9) | | | | | $ | 738,858 | | |
Daron Evans
|
| | | | 2024 | | | | | $ | 121,267(3) | | | | | $ | 59,734(4) | | | | | $ | 201,025(6) | | | | | $ | 2,039(10) | | | | | $ | 384,065 | | |
Chief Financial Officer
|
| | | | 2023 | | | | | $ | —(11) | | | | | $ | —(11) | | | | | $ | —(11) | | | | | $ | —(11) | | | | | $ | — | | |
| | |
Grant
Date |
| |
Number of Securities Underlying
Unexercised Options |
| |
Option
Exercise Price |
| |
Option
Expiration Date |
| ||||||||||||||||||
Name
|
| |
Exercisable
|
| |
Unexercisable
|
| ||||||||||||||||||||||||
Nevan Charles Elam
|
| | | | 7/31/19 | | | | | | 200,000 | | | | | | — | | | | | $ | 14.50 | | | | | | 7/31/29 | | |
| | | | | 6/14/21 | | | | | | 250,000 | | | | | | 125,000(1) | | | | | | 12.28 | | | | | | 6/14/31 | | |
| | | | | 6/23/22 | | | | | | 650,000 | | | | | | 1,950,000(3) | | | | | | 3.40 | | | | | | 6/23/32 | | |
| | | | | 1/23/24 | | | | | | 47,222 | | | | | | 292,778(4) | | | | | | 1.02 | | | | | | 1/23/34 | | |
Total for Mr. Elam
|
| | | | | | | | | | 1,147,222 | | | | | | 2,367,778 | | | | | | | | | | | | | | |
Brian Roberts, M.D.
|
| | | | 7/31/19 | | | | | | 40,000 | | | | | | — | | | | | $ | 14.50 | | | | | | 7/31/29 | | |
| | | | | 6/14/21 | | | | | | 56,250 | | | | | | 18,750(2) | | | | | | 12.28 | | | | | | 6/14/31 | | |
| | | | | 6/23/22 | | | | | | 175,000 | | | | | | 525,000(3) | | | | | | 3.40 | | | | | | 6/23/32 | | |
| | | | | 1/23/24 | | | | | | 18,055 | | | | | | 111,945(4) | | | | | | 1.02 | | | | | | 1/23/34 | | |
Total for Dr. Roberts
|
| | | | | | | | | | 289,305 | | | | | | 655,695 | | | | | | | | | | | | | | |
Daron Evans
|
| | | | 1/23/24 | | | | | | — | | | | | | 275,000(5) | | | | | $ | 1.02 | | | | | | 1/23/29 | | |
Total for Mr. Evans
|
| | | | | | | | | | — | | | | | | 275,000(6) | | | | | | | | | | | | | | |
Pay Versus Performance Table
|
| ||||||||||||||||||||||||||||||||||||
Fiscal Year(1)
|
| |
Summary
Compensation Table Total for PEO(2) |
| |
Compensation
Actually Paid to PEO(3) |
| |
Average
Summary Compensation Table Total for Non-PEO NEOs(2) |
| |
Average
Compensation Actually Paid to Non-PEO NEOs(4) |
| |
Value of Initial
Fixed $100 Investment Based On Rezolute Total Stockholder Return(5) |
| |
Net
Income(6) |
| ||||||||||||||||||
2024
|
| | | $ | 1,192,700 | | | | | $ | 4,958,776 | | | | | $ | 601,012 | | | | | $ | 1,568,002 | | | | | $ | 30 | | | | | $ | (68,459,000) | | |
2023
|
| | | $ | 973,646 | | | | | $ | (1,958,066) | | | | | $ | 738,858 | | | | | $ | (30,316) | | | | | $ | 14 | | | | | $ | (51,787,000) | | |
2022
|
| | | $ | 7,781,300 | | | | | $ | 3,572,820 | | | | | $ | 2,423,148 | | | | | $ | 1,699,320 | | | | | $ | 23 | | | | | $ | (41,060,000) | | |
PEO
|
| |||||||||||||||||||||
| | | | | |
2022
|
| |
2023
|
| |
2024
|
| |||||||||
| | |
Summary Compensation Table — Total Compensation(a)
|
| | | $ | 7,781,300 | | | | | $ | 973,646 | | | | | $ | 1,192,700 | | |
- | | |
Grant Date Fair Value of Stock Awards and Option Awards
Granted in Fiscal Year(b) |
| | | $ | 6,862,960 | | | | | $ | — | | | | | $ | 227,032 | | |
+ | | |
Fair Value at Covered Fiscal Year End of All Outstanding
and Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year(c) |
| | | $ | 6,237,785 | | | | | $ | — | | | | | $ | 1,155,477 | | |
+ | | |
Change in Fair Value as of Prior Fiscal Year End of Any
Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year(d) |
| | | $ | (2,393,356) | | | | | $ | (2,265,885) | | | | | $ | 2,754,621 | | |
+ | | |
Fair Value at Vesting Date of Stock Awards and Option
Awards Granted in Covered Fiscal Year That Vested During Covered Fiscal Year(e) |
| | | $ | — | | | | | $ | — | | | | | $ | 114,525 | | |
+ | | |
Change in Fair Value as of Vesting Date of Any Stock
Awards and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year(f) |
| | | $ | (1,189,949) | | | | | $ | (665,827) | | | | | $ | (31,515) | | |
- | | |
Fair Value as of Prior Fiscal Year End of Any Stock Awards
and Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year(g) |
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
= | | |
Compensation Actually Paid
|
| | | $ | 3,572,820 | | | | | $ | (1,958,066) | | | | | $ | 4,958,776 | | |
NEO Average
|
| |||||||||||||||||||||
| | | | | |
2022
|
| |
2023
|
| |
2024
|
| |||||||||
| | |
Summary Compensation Table — Total Compensation(a)
|
| | | $ | 2,423,148 | | | | | $ | 738,858 | | | | | $ | 601,012 | | |
- | | |
Grant Date Fair Value of Stock Awards and Option Awards
Granted in Fiscal Year(b) |
| | | $ | 1,847,720 | | | | | $ | — | | | | | $ | 153,475 | | |
+ | | |
Fair Value at Covered Fiscal Year End of All Outstanding and
Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year(c) |
| | | $ | 1,679,404 | | | | | $ | — | | | | | $ | 731,761 | | |
+ | | |
Change in Fair Value as of Prior Fiscal Year End of Any
Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year(d) |
| | | $ | (360,815) | | | | | $ | (598,192) | | | | | $ | 370,814 | | |
+ | | |
Fair Value at Vesting Date of Stock Awards and Option
Awards Granted in Covered Fiscal Year That Vested During Covered Fiscal Year(e) |
| | | $ | — | | | | | $ | — | | | | | $ | 21,894 | | |
+ | | |
Change in Fair Value as of Vesting Date of Any Stock Awards
and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year(f) |
| | | $ | (194,697) | | | | | $ | (170,982) | | | | | $ | (4,004) | | |
NEO Average
|
| |||||||||||||||||||||
| | | | | |
2022
|
| |
2023
|
| |
2024
|
| |||||||||
- | | |
Fair Value as of Prior Fiscal Year End of Any Stock Awards
and Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year(g) |
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
= | | |
Compensation Actually Paid
|
| | | $ | 1,699,320 | | | | | $ | (30,316) | | | | | $ | 1,568,002 | | |
SHARE INCREASE PROPOSAL
AMENDMENT OF 2021 INCENTIVE COMPENSATION PLAN
ADJOURNMENT PROPOSAL
TO THE REZOLUTE, INC. 2021 EQUITY INCENTIVE PLAN
Title: Chief Executive Officer
TO
THE AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF
REZOLUTE, INC.
Title: Chief Executive Officer